SEC Comment Letter 0000000000-25-003067 to Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc.
Date: March 21, 2025 · CIK: 0001785279 · Accession: 0000000000-25-003067
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285867
Letter
Re: Metagenomi, Inc. Registration Statement on Form S-3 Filed March 17, 2025 File No. 333-285867 Dear Brian C. Thomas:
March 21, 2025
Brian C. Thomas Chief Executive Officer Metagenomi, Inc. 5959 Horton Street, 7th Floor Emeryville, CA 94608
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Justin Platt
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 21, 2025 Brian C. Thomas Chief Executive Officer Metagenomi, Inc. 5959 Horton Street, 7th Floor Emeryville, CA 94608 Re: Metagenomi, Inc. Registration Statement on Form S-3 Filed March 17, 2025 File No. 333-285867 Dear Brian C. Thomas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin Platt </TEXT> </DOCUMENT>